Market
What will be the outcome of AMT-130 Phase I/II trials by Q1 2025?
2
Resolution / Starting Odds
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Worse outcomes • 25%
Publication of trial results or uniQure announcements
Story
uniQure Gains FDA Alignment on Accelerated Approval Pathway Using cUHDRS for Huntington's Gene Therapy AMT-130
Dec 10, 2024, 01:04 PM
uniQure ($QURE) announced that it has aligned with the U.S. Food and Drug Administration (FDA) on key elements of an Accelerated Approval pathway for its gene therapy candidate AMT-130 in Huntington’s Disease. The FDA agreed that data from the ongoing Phase I/II studies, when compared to a natural history external control, may serve as the primary basis for a Biologics License Application (BLA) submission under the Accelerated Approval program. Additionally, the composite Unified Huntington's Disease Rating Scale (cUHDRS) may serve as an intermediate clinical endpoint. The company has previously presented 24-month data showing superiority over natural history controls. This regulatory alignment is significant as it could expedite the approval process for AMT-130, potentially offering a much-needed treatment for patients with Huntington's Disease. The announcement led to a substantial increase in uniQure's stock price, which more than doubled in pre-market trading.
View original story
Similar markets
No improvement • 25%
Worsening condition • 25%
Significant improvement • 25%
Moderate improvement • 25%
Rejection • 25%
Full Approval • 25%
Accelerated Approval • 25%
Conditional Approval • 25%
Negative results • 25%
Trial discontinued • 25%
Positive results with MRD-negative CR • 25%
Mixed results • 25%
Negative immunogenicity results • 25%
Positive safety and immunogenicity results • 25%
Study inconclusive • 25%
Negative safety results • 25%
Positive efficacy and safety results • 25%
Positive efficacy, but safety concerns • 25%
Negative efficacy, but good safety • 25%
Negative efficacy and safety concerns • 25%
Successful with moderate efficacy • 25%
Trial inconclusive • 25%
Unsuccessful • 25%
Successful with high efficacy • 25%
Ongoing • 25%
Unsuccessful • 25%
Successful without FDA approval • 25%
Successful with FDA approval • 25%
Unsuccessful trial • 33%
Inconclusive results • 34%
Successful trial • 33%
Other outcome • 25%
Negative results halting development • 25%
Neutral results requiring further study • 25%
Positive results leading to Phase 2 • 25%
Unsuccessful • 25%
Successful with FDA approval recommendation • 25%
Successful without FDA approval recommendation • 25%
Delayed • 25%